Intravitreal conbercept for choroidal neovascularisation secondary to pathological myopia in a real-world setting in China Intravitreal conbercept was safe and effective in treating myopic choroidal neovascularization

Background To evaluate the 12-month efficacy and safety of intravitreal conbercept for myopic choroidal neovascularization (CNV). Methods A retrospective, observational study. Thirty-four eyes of 34 pathologic myopic patients with CNV were treated with intravitreal conbercept (IVC) 0.5 mg with a follow up of 12 months. After the first injection, administration of conbercept followed a pro re nata (PRN) regimen. Outcomes included best corrected visual acuity (BCVA), central retinal thickness (CRT), CNV size, the total number of treatments, and adverse events. Results The mean patient age was 55.88 +/- 16.17 years, and the mean eye spherical equivalent was - 8.72 +/- 3.75 D. The mean number of IVC over 12 months was 2.12 +/- 0.69. Overall, best-corrected visual acuity(BCVA)improved from 0.86 +/- 0.33 logMAR at baseline to 0.44 +/- 0.32 logMAR at month 12 (p < 0.001), mean improvement of vision was 4.12 +/- 2.69 lines. Mean central retinal thickness reduced from 285.9 +/- 104.6 mu m at baseline to 192.1 +/- 97.5 mu m at month 12 (p < 0.001). Mean CNV size decreased from 0.52 +/- 0.38 mm(2) at baseline to 0.31 +/- 0.19 mm(2) at 12 months (p < 0.05). All the 34 eyes had reduced or stable size of CNV. Thirty-two eyes (94.12 %) showed the absence of CNV leakage at the end of the study period. No severe systemic or ocular adverse events were observed. Conclusions Intravitreal conbercept 0.5 mg was safe and effective for treatment of myopic CNV over 12 months in a real-world setting.